Trial Profile
A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DPPIVinHIV
- 25 Jun 2012 Actual patient number is 20 according to ClinicalTrials.gov.
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.